Danazol: objective assessment in the treatment of endometriosis.
The objective assessment of Danocrine (Danazol, Winthrop) in the treatment of endometriosis was hampered in the 1970s by the absence of a universally accepted classification. The American Fertility Society (AFS) classification, proposed in 1979, has now become widely accepted. However, there is a lack of recorded objective data utilizing the AFS score before and after Danazol therapy. In a series of 51 patients with endometriosis, who underwent laparoscopy, then received Danazol, 800 mg daily for 6 months, and had a repeat laparoscopy, there was a statistically significant improvement in the AFS score in Stage I and II disease.
D003613:Danazol / Q000627:therapeutic use*; D004341:Drug Evaluation; D004715:Endometriosis / Q000145:classification / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D010535:Laparoscopy; D011245:Pregnadienes / Q000627:therapeutic use*
D011245:Pregnadienes; D003613:Danazol